Musely Lands $360 Million From General Catalyst in Rare Non-Dilutive Deal

Direct-to-consumer healthcare brand Musely has locked in $360 million in non-dilutive capital from General Catalyst. The massive funding deal is structured similarly to a loan rather than a traditional venture capital round, meaning the company’s founders and existing shareholders do not have to give up any equity to access the cash.

Specializing in prescription skincare, hair growth treatments, and menopause care, Musely plans to use the capital to aggressively scale its customer acquisition efforts. The company operates at the intersection of telemedicine and e-commerce, offering custom-compounded medications that require a physician's oversight via a digital platform.

This deal highlights a growing trend in the tech sector where mature, revenue-generating startups opt for alternative financing to avoid valuation markdowns or dilution. By choosing a credit-based structure over equity, Musely maintains full control over its board and operations while gaining a war chest to compete in the crowded wellness market.

Industry observers will be watching to see if this influx of capital allows Musely to dominate the prescription-strength aesthetic market. As digital health companies face tightening private markets, this move sets a precedent for how established brands can fuel growth without the typical pitfalls of venture fundraising. TechCrunch first reported the details of the financing arrangement.